Schistosomiasis, hepatitis B and hepatitis C co-infection

Virology Journal

Ishag Adam²  Abdelhaleem Bella³  Gasim I Gasim¹ 

[1] Qassim College of Medicine, Qassim University, Buraydah, Saudi Arabia;Faculty of Medicine, University of Khartoum, Khartoum, Sudan;King Fahad Hospital of the University, University of Dammam, Dammam, Saudi Arabia

关键词: Adjuvant;    Vaccine;    Hepatotropic;    HCV;    HBV;    Schistosomiasis;   

Others  :  1131012
DOI  :  10.1186/s12985-015-0251-2

 received in 2014-10-19, accepted in 2015-01-29,  发布年份 2015

【 摘 要 】

Background

Schistosomiasis is a significant health problem in more than 70 countries distributed between Africa, Asia and South America, with an infection rate of one in 30 individuals. Data on Schistosomiasis, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection are scarce; however, there is a high prevalence in countries where schistosomiasis is endemic.

Methods

A systematic search was performed on published data from 1980–2014. Published papers in the databases Google, Medline, PubMed, and MiPc library were searched using the keywords epidemiology, pathogenesis and outcomes of HBV, HCV and schistosomiasis and data were extracted from the relevant studies.

Results

The prevalence of HBV/schistosomiasis co-infection in countries where schistosomiasis is endemic was high, ranging between 9.6 to approximately 64% in Egypt, and a maximum of 15.8% among hospitalized patients in Brazil. Concurrent infection between HBV and schistosomiasis is often associated with countries where schistosomiasis is endemic and may lead to chronic liver inflammation. Similarly, HCV infection rates in schistosomiasis populations range from 1% in Ethiopia reaching up to 50% in Egypt.

Conclusion

There is controversy regarding the effects of HBV and HCV on schistosomiasis and vice versa. Vaccination might be a solution to the era of schistosomiasis and co-infection with HBV and HCV.

【 授权许可】

   
2015 Gasim et al.; licensee BioMed Central.

【 参考文献 】

• [1]WHO: Status of Schistosomiasis endemic countries. Geneva: World Health Organization; 2012. apps.who.int/neglected_diseases/ ntddata/sch/sch.html.
• [2]Schistosomiasis Control Program: The Carter Center http://www.cartercenter.org/resources/pdfs/factsheets/schistosomiasis-facts.pdf>. Accessed 2011 Nov 15.
• [3]Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6:411-25.
• [4]Barakat RM: Epidemiology of Schistosomiasis in Egypt: travel through time: review. J Adv Res 2013, 4:425-32.
• [5]Knopp S, Person B, Ame SM, Mohammed KA, Ali SM, Khamis IS, Rabone M, Allan F, Gouvras A, Blair L, Fenwick A, Utzinger J, Rollinson D: Elimination of schistosomiasis transmission in Zanzibar: baseline findings before the onset of a randomized intervention trial. PLoS Negl Trop Dis 2013, 7:e2474.
• [6]Schmitt, I: Schistosomiasis—The burden of disease and trends of intervention. International Health Practice; April 2006. http://www.case.edu/med/epidbio/mphp439/Schistosomiasis.htm.
• [7]Blanton RE, Salam EA, Kariuki HC, Magak P, Silva LK, Muchiri EM, Thiongo F, Abdel-Meghid IE, Butterworth AE, Reis MG, Ouma JH: Population-based differences in Schistosomiasis mansoni and hepatitis C induced disease. J Infect Dis 1859, 2002:1644-9.
• [8]Boisier P, Ramarokoto CE, Ravoniarimbinina P, Rabarijaona L, Ravaoalimalala VE: Geographic diffrerences in hepatosplenic complications of Schistosomiasis mansoni and explanatory factors of morbidity. Trop Med Int Health 2001, 6:699-706.
• [9]Dessein AJ, Hillaire D, Elwali NE, Marquet S, Mohamed-Ali Q, Mirghani A, Henri S, Abdelhameed AA, Saeed OK, Magzoub MM, Abel L: Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet 1999, 65:709-21.
• [10]King CH, Magak P, Abdel-Salam E, Ouma JH, Kariuki HC, Blanton E: Measuring morbidity in Schistosomiasis mansoni: relationship between image pattern, portal vein diameter and portal branch thickness in large-scale surveys using new WHO coding guidelines for ultrasound in schistosomiais. Trop Med Int Health 2003, 8:109-17.
• [11]Mohamed-Ali Q, Elwali NE, Abdelhameed AA, Mergani A, Rahoud S, Elagib KE, Saeed OK, Abel L, Magzoub MM, Dessein AJ: Susceptibility to periportal (Symmers) fibrosis in human Schistosoma mansoni infections: evidence that intensity and duration of infection, gender and inherited factors are critical in disease progression. J Infect Dis 1999, 180:1298-306.
• [12]Elbaz T, Esmat G: Hepatic and Intestinal Schistosomiasis: Review. JAR 2013, 4:445-52.
• [13]Pereira LM, Domingues AL, Spinelli V, McFarlane IG: Ultrasonography of the liver and spleen in Brazilian patients with hepatosplenic Schistosomiasis and cirrhosis. Trans R Soc Trop Med Hyg 1998, 92:639-42.
• [14]Conceic¸a˜o MJ, Argento CA, Chagas VL, Takiya CM, Moura DC, Silva SC: Prognosis of Schistosomiasis mansoni patients infected with hepatitis B virus. Mem Inst Oswaldo Cruz 1998, 93:255-8.
• [15]El-Masry S, Lotfy M, El-Shahat M, Badra G: Serum laminin assayed by Slot-Blot-ELISA in patients with combined viral hepatitis C and schistosomiasis. Clin Biochem 2006, 39:652-7.
• [16]Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH: Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-9.
• [17]Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed KK, Peter T, Mansour H, Ezzat W, Koziel M: Acute hepatitis C without and with Schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001, 121:646-56.
• [18]Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-42.
• [19]Barnard H: Hepatitis C in Egypt, a iatrogenic epidemy. Ned Tijdschr Geneeskd 2000, 144:2024-5.
• [20]El-Sayed HF, Abaza SM, Mehanna S, Winch PJ: The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop 1997, 68:229-37.
• [21]Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, De Santis A, Nagi A, Amin G, Capocaccia L, Callea F, Rapicetta M, Badr G, Rocchi G: Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997, 26:236-43.
• [22]Aquino RT, Chieffi PP, Catunda SM, Araújo MF, Ribeiro MC, Taddeo EF, Rolim EG: Hepatitis B and C virus markers among patients with hepatosplenic mansonic schistosomiasis. Rev Inst Med Trop Sao Paulo 2000, 42:313-20.
• [23]Du H: Relationship between advanced schistosomiasis and HBV infection. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2013, 25:115-117.
• [24]Van-Lume DS, Albuquerque Mde F, Souza AI, Domingues AL, Lopes EP, Morais CN, Montenegro SM: Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica 2013, 47:414-24.
• [25]Mudawi HM, Smith HM, Fletcher IA, Fedail SS: Prevalence and common genotypes of HCV infection in Sudanese patients with hepatosplenic schistosomiasis. J Med Virol 2007, 79:1322-4.
• [26]Li Y, Chen D, Ross AG, Burke ML, Yu X, Li RS, et al.: Severe hepatosplenic schistosomiasis: clinicopathologic study of 102 cases undergoing splenectomy. Hum Pathol 2011, 42:111-9.
• [27]El-Esnawy NA, Al-Herrawy AZ: Seroprevalence of certain hepatitis viruses among Egyptian workers infected with schistosomiasis. J Egypt Public Health Assoc 2000, 75:357-66.
• [28]Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, et al.: Co infection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. World J Gastroenterol 2013, 19:2691-6.
• [29]Al-Shamiri AH, Al-Taj MA, Ahmed AS: Prevalence and co-infections of Schistosomiasis/hepatitis B and C viruses among school children in an endemic area in Taiz, Yemen. Asian Pac J Trop Med 2011, 4:404-8.
• [30]Berhe N, Myrvang B, Gundersen SG: Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia. Am J Trop Med Hyg 2007, 77:1079-86.
• [31]Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Anwar W, Strickland GT, Fix AD, Sallam I: Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001, 33:248-53.
• [32]Silva JLA, Coelho MRCD, Souza VSB, Domingues ALC: Soroprevalência da hepatite C em pacientes com esquistossomose. Rev Para Med 2008, 22:27-32.
• [33]Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ: The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013, 13:288. BioMed Central Full Text
• [34]Silva JLA, Souza VSB, Vilella TAS, Domingues ALC, Coêlho MRCD: Marcadores sorológicos do VHB e VHC em pacientes com esquistossomose mansônica na forma hepatoesplênica. Arq Gastroenterol 2011, 48:124-30.
• [35]Edris A, Nour MO, Zedan OO, Mansour AE, Ghandour AA, Omran T: Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate. Egypt. East Mediterr Health J 2014, 20:605-13.
• [36]Wahib AA, Masoud AA, Halem AA, Haseeb AN, Hassan AR, Darwish MA, Hegazi M, Abdallah KF: Cell mediated immune response in chronic liver diseases: schistosomal, viral and neoplastic. J Egypt Soc Parasitol 1998, 28:929-39.
• [37]Edwards MJ, Buchatska O, Ashton M, Montoya M, Bickle QD, Borrow P: Reciprocal immunomodulation in a schistosome and hepatotropic virus coinfection model. J Immunol 2005, 175:6275-85.
• [38]Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, Li YL, Wang T: Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One 2012, 7:e51512.
• [39]Chen SL, Morgan TR: The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci 2006, 3:47-52.
• [40]Elrefaei M, El-Sheikh N, Kamal K, Cao H: HCV-specific CD27–CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection. Immunology 2003, 110:513-8.
• [41]Makhlouf LM, Serwah Ael H, Abd El-Hamid Ael D, Hussein EM, Saad RM: INF-gamma, IL-5 and IgE profiles in chronic Schistosomiasis mansoni Egyptian patients with or without hepatitis C infection. J Egypt Soc Parasitol 2006, 36:177-96.
• [42]Emam EA, Emam M, Shehata AE, Emara M: Impact of Schistosoma mansoni co-infection on serum profile of interferon-gamma, interleukin-4 and interleukin-10 in patients with chronic hepatitis C virus infection. Egypt J Immunol 2006, 13:33-40.
• [43]El-Awady MK, Youssef SS, Omran MH, Tabll AA, El Garf WT, Salem AM: Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection. BMC Infect Dis 2006, 6:91. BioMed Central Full Text
• [44]Elsammak MY, Al-Sharkaweey RM, Ragab MS, Amin GM, Kandil MH: In Egyptians, a mutation in the lymphotoxin-alpha gene may increase susceptibility to hepatitis C virus but not that to Schistosomal infection. Ann Trop Med Parasitol 2008, 102:709-16.
• [45]Abbas OM, Abdel-Rahman MH, Omar NA, Badran HM, Amir EM: Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection. Liver Int 2009, 29:1422-30.
• [46]Hammad HA, el Fattah MM, Moris M, Madina EH, el Abbasy AA, Soliman AT: Study on some hepatic functions and prevalence of hepatitis B surface antigenaemiain Egyptian children with Schistosomal hepatic fibrosis. J Trop Pediatr 1990, 36:126-7.
• [47]Al-Freihi HM: Prevalence of hepatitis B surface antigenemia among patients with Schistosoma mansoni. Ann Saudi Med 1993, 13:121-5.
• [48]Larouze B, Dazza MC, Gaudebout C, Habib M, Elamy M, Cline B: Absence of relationship between Schistosoma mansoni and hepatitis B virus infection in the Qalyub Governate, Egypt. Ann Trop Med Parasitol 1987, 81:373-5.
• [49]Ye XP, Fu YL, Anderson RM, Nokes DJ: Absence of relationship between Schistosoma japonicum and hepatitis B virus infection in the Dongting lake region, China. Epidemiology and Infection 1998, 121:193-5.
• [50]Andrade ZA, Berthillon P, Paraná R, Grimaud JA, Trépo C: Schistosomiasis mansoni and viral B hepatitis in woodchucks. J Hepatol 2001, 34:134-9.
• [51]Osada Y, Kanazawa T: Schistosome: its benefit and harm in patients suffering from concomitant diseases. J Biomed Biotechnol 2011, 2011:264173.
• [52]McClary H, Koch R, Chisari FV, Guidotti LG: Inhibition of hepatitis B virus replication during Schistosoma mansoni infection in transgenic mice. J Exp Med 2000, 192:289-94.
• [53]Maria José Conceição and José Rodrigues Coura (2013): Study on Schistosomiasis mansoni and Comorbidity with Hepatitis B and C Virus Infection, Parasitic Diseases - Schistosomiasis, Prof. Rashika El Ridi (Ed.), ISBN: 978-953-51-0942-6, InTech. Available from: http://www.intechopen.com/books/parasitic-diseases-Schistosomiasis/study-on-Schistosomiasis-mansoni-and-comorbidity-with-hepatitis-b-and-c-virus-infection
• [54]Andrade JR, Silva LD, Guimarães CM, Bassetti-Soares E, Cambraia RD, Couto OF, Teixeira R: Chronic hepatitis B and liver schistosomiasis: a deleterious association. Trans R Soc Trop Med Hyg 2014, 108:159-64.
• [55]Lundy SK, Lukacs NW: Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression. Front Immunol 2013, 4:39.
• [56]Bassily S, Strickland GT, Abdel-Wahab MF, Esmat GE, Narooz S, el-Masry NA, Constantine NT, Struewing JP: “Efficacy of hepatitis B vaccination in primary school children from a village endemic for Schistosoma mansoni,”. J Infect Dis 1992, 166:265-8.
• [57]Mohamed A, Elsheikh A, Ghandour Z, Al Karawi M: Impact of hepatitis C virus infection on Schistosomal liver disease. Hepatogastroenterology 1998, 45:1492-6.
• [58]Gad A, Tanaka E, Orii K, Rokuhara A, Nooman Z, Serwah AH, Shoair M, Yoshizawa K, Kiyosawa K: Relationship between hepatitis C virus infection and Schistosomal liver disease: not simply an additive effect. J Gastroenterol 2001, 36:753-8.
• [59]Allam WR, Barakat A, Zakaria Z, Galal G, Abdel-Ghafar TS, El-Tabbakh M, Mikhail N, Waked I, Abdelwahab SF: Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. Am J Trop Med Hyg 2014, 90:823-9.
• [60]Keang H, Odermatt P, Odermatt-Biays S, Cheam S, Degremont A, Hatz C: Liver morbidity due to Schistosoma mekongi in Cambodia after seven rounds of mass drug administration. Trans R Soc Trop Med Hyg 2007, 101:759-65.
• [61]Huang LH, Qiu YW, Hua HY, Niu XH, Wu PF, Wu HY, Zhu HY, Yang XJ, Yao SZ, Li YG: The efficacy and safety of entecavir in patients with advanced Schistosomiasis co-infected with hepatitis B virus. Int J Infect Dis 2013, 17:e606-609.
• [62]Draz HM, Mahmoud SS, Ashour E, Shaker YM, Wu CH, Wu GY: Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol 2010, 96:703-8.
• [63]Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, Al-Marri A, Amer AM, Morad N, Bener A: Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006, 12:5692-8.
• [64]Tian Z, Wang SP, Zeng SH, Liu XQ, Gao DM, Feng QM, Zhang SJ, Zhou YF, Wang XY, Xia YD: Characterization and vaccination of two novel Schistosoma japonicum genes screened from a cercaria cDNA library. Parasitol Res 2012, 110:403-9.
• [65]Qiu C, Liu S, Hong Y, Fu Z, Wei M, Ai D, Lin J: Molecular characterization of thyroid hormone receptor beta from Schistosoma japonicum and assessment of its potential as a vaccine candidate antigen against Schistosomiasis in BALB/c mice. Parasit Vectors 2012, 13:5-172.
• [66]Gray DJ, Li YS, Williams GM, Zhao ZY, Harn DA, Li SM, Ren MY, Feng Z, Guo FY, Guo JG, Zhou J, Dong YL, Li Y, Ross AG, McManus DP. A multi-component integrated approach for the elimination of Schistosomiasis in the People's Republic of China: design and baseline results of a 4-year cluster-randomised intervention trial. Int J Parasitol. 2014 pii, S0020-751900136-2.
• [67]Espíndola MS, Frantz FG, Soares LS, Masson AP, Tefé-Silva C, Bitencourt CS, Oliveira SC, Rodrigues V, Ramos SG, Silva CL, Faccioli LH: Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection. BMC Infect Dis 2014, 14:263. BioMed Central Full Text
• [68]Zhang W, Ahmad G, Le L, Rojo JU, Karmakar S, Tillery KA, Torben W, Damian RT, Wolf RF, White GL, Carey DW, Carter D, Reed SG, Siddiqui AA: Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res 2014, 113:2239-50.
• [69]Moyle PM, Toth I: Self-Adjuvanting lipopeptide vaccines. Curr Med Chem 2008, 15:506-16.
• [70]Garcia A, Fernandez S, Toro F, De Sanctis JB: An Overview Of Hepatitis C Vaccines. Recent Pat Inflamm Allergy Drug Discov 2014, 8:85-91.
• [71]Baldo V, Bonanni P, Castro M, Gabutti G, Franco E, Marchetti F, Prato R, Vitale F: Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine; Infanrix™ hexa: Twelve years of experience in Italy. Hum Vaccin Immunother 2014, 10:129-37.
• [72]Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D: A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 2013, 32:521-9.